Effect of Smoking and Folate Levels on the Efficacy of Folic Acid Therapy in Prevention of Stroke in Hypertensive Men
This article has a correction. Please see:

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Background and Purpose—We aimed to examine whether the efficacy of folic acid therapy in the primary prevention of stroke is jointly affected by smoking status and baseline folate levels in a male population in a post hoc analysis of the CSPPT (China Stroke Primary Prevention Trial).
Methods—Eligible participants of the CSPPT were randomly assigned to a double-blind daily treatment of a combined enalapril 10-mg and folic acid 0.8-mg tablet or an enalapril 10-mg tablet alone. In total, 8384 male participants of the CSPPT were included in the current analyses. The primary outcome was first stroke.
Results—The median treatment duration was 4.5 years. In the enalapril-alone group, the first stroke risk varied by baseline folate levels and smoking status (never versus ever). Specifically, there was an inverse association between folate levels and first stroke in never smokers (P for linear trend=0.043). However, no such association was found in ever smokers. A test for interaction between baseline folate levels and smoking status on first stroke was significant (P=0.045). In the total sample, folic acid therapy significantly reduced the risk of first stroke in never smokers with folate deficiency (hazard risk, 0.36; 95% confidence interval, 0.16–0.83) and in ever smokers with normal folate levels (hazard risk, 0.69; 95% confidence interval, 0.48–0.99).
Conclusions—Baseline folate levels and smoking status can interactively affect the risk of first stroke. Our data suggest that compared with never smokers, ever smokers may require a higher dosage of folic acid to achieve a greater beneficial effect on stroke. Our findings need to be confirmed by future randomized trials.
Clinical Trial Registration—URL: https://www.clinicaltrials.gov. Unique identifier: NCT00794885.
- Received June 19, 2017.
- Revision received October 19, 2017.
- Accepted October 24, 2017.
- © 2017 American Heart Association, Inc.
American Heart Association Professional?
Log in using your username and password
Pay Per Article - You may access this article (from the computer you are currently using) for 1 day for US$35.00
Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.
Jump to
This Issue
Article Tools
- Effect of Smoking and Folate Levels on the Efficacy of Folic Acid Therapy in Prevention of Stroke in Hypertensive MenZiyi Zhou, Jianping Li, Yaren Yu, Youbao Li, Yan Zhang, Lishun Liu, Yun Song, Min Zhao, Yu Wang, Genfu Tang, Mingli He, Xiping Xu, Yefeng Cai, Qiang Dong, Delu Yin, Xiao Huang, Xiaoshu Cheng, Binyan Wang, Fan Fan Hou, Xiaobin Wang, Xianhui Qin and Yong HuoStroke. 2018;49:114-120, originally published December 22, 2017https://doi.org/10.1161/STROKEAHA.117.018273
Citation Manager Formats
Share this Article
- Effect of Smoking and Folate Levels on the Efficacy of Folic Acid Therapy in Prevention of Stroke in Hypertensive MenZiyi Zhou, Jianping Li, Yaren Yu, Youbao Li, Yan Zhang, Lishun Liu, Yun Song, Min Zhao, Yu Wang, Genfu Tang, Mingli He, Xiping Xu, Yefeng Cai, Qiang Dong, Delu Yin, Xiao Huang, Xiaoshu Cheng, Binyan Wang, Fan Fan Hou, Xiaobin Wang, Xianhui Qin and Yong HuoStroke. 2018;49:114-120, originally published December 22, 2017https://doi.org/10.1161/STROKEAHA.117.018273







